Y-mAbs Therapeutics, Inc.

YMAB

US9842411095

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 05/07/2024 BST			5-day change	1st Jan Change
11.4 ^USD	+0.18%		-5.63%	+67.16%

07-01	Y-mAbs Therapeutics Appoints Peter Pfreundschuh as CFO	MT
07-01	Y-mAbs Therapeutics, Inc. Announces the Appointment of Peter Pfreundschuh as Chief Financial Officer	CI

Y-mAbs Therapeutics, Inc.(NasdaqGS:YMAB) dropped from Russell 3000 Value Index

July 30, 2024

Latest news about Y-mAbs Therapeutics, Inc.

Y-mAbs Therapeutics Appoints Peter Pfreundschuh as CFO	07-01	MT
Y-mAbs Therapeutics, Inc. Announces the Appointment of Peter Pfreundschuh as Chief Financial Officer	07-01	CI
Y-mAbs Therapeutics, Inc.(NasdaqGS:YMAB) dropped from Russell Microcap Value Index	06-30	CI
Y-mAbs Therapeutics, Inc.(NasdaqGS:YMAB) dropped from Russell 3000E Value Index	06-30	CI
Y-mAbs Therapeutics, Inc.(NasdaqGS:YMAB) dropped from Russell 2000 Value Index	06-30	CI
Y-mAbs Therapeutics, Inc.(NasdaqGS:YMAB) dropped from Russell 3000 Value Index	06-30	CI
Y-mAbs Therapeutics, Inc.(NasdaqGS:YMAB) dropped from Russell 2500 Value Index	06-30	CI
Y-mAbs Therapeutics, Inc.(NasdaqGS:YMAB) dropped from Russell Small Cap Comp Value Index	06-30	CI
Truist Initiates Y-mAbs Therapeutics at Buy With $21 Price Target, Calls Radioimmunotherapy Platform 'Undervalued'	06-28	MT
Y-mAbs Therapeutics, Inc. Appoints Norman LaFrance as Chief Development Officer	06-05	CI
Y-mAbs Therapeutics, Inc. Announces Publication of Preclinical GD2-SADA Data	06-01	CI
Y-mAbs Therapeutics, Inc. Announces New Interim Analysis of Phase 2 Data for Naxitamab At 2024 Asco Annual Meeting	06-01	CI
Transcript : Y-mAbs Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024	05-08
Earnings Flash (YMAB) Y-MABS THERAPEUTICS Posts Q1 Revenue $19.9M, vs. Street Est of $22.2M	05-07	MT
Y-mAbs Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07	CI
Y-mAbs Therapeutics, Inc. Announces Resignation of Gérard Ber, Ph.D. from the Board of Directors, Effective June 10, 2024	04-29	CI
Y-mAbs Therapeutics Chief Financial Officer Bo Kruse to Resign	03-14	MT
Y-mAbs Therapeutics, Inc. Announces Resignation of Bo Kruse as Executive Vice President, Secretary and Treasurer, Effective July 31, 2024	03-14	CI
Y-mAbs Therapeutics Announces Resignation of Bo Kruse as Chief Financial Officer	03-14	CI
HC Wainwright Adjusts Price Target on Y-mAbs Therapeutics to $22 From $21, Keeps Buy Rating	03-06	MT
Canaccord Genuity Raises Price Target on Y-mAbs Therapeutics to $26 From $22, Maintains Buy Rating	03-04	MT
BMO Capital Adjusts Y-mAbs Therapeutics Price Target to $26 From $16, Maintains Outperform Rating	03-04	MT
Y-mAbs Therapeutics, Inc. Appoints Mary Tagliaferri to Its Board of Directors	03-04	CI
Wedbush Raises Y-mAbs Therapeutics' PT to $23 From $18 After Higher-Than-Expected Q4 2023 Danyelza Net Product Revenue, Maintains Outperform Rating	03-04	MT
Transcript : Y-mAbs Therapeutics, Inc., Q4 2023 Earnings Call, Mar 01, 2024	03-01

Chart Y-mAbs Therapeutics, Inc.

Duration

Period

More charts

Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. Its technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform and bispecific antibodies generated using the Y-BiClone platform. Its advanced product pipeline includes the anti-GD2 therapy DANYELZA (naxitamab-gqgk), a food and drug administration (FDA)-approved treatment for patients with relapsed or refractory neuroblastoma in the bone or bone marrow after a partial response, minor response or stable disease to prior therapy. DANYELZA is a humanized immunoglobulin G, subtype 1k (IgG1k), monoclonal antibody (mAb), that targets ganglioside GD2, which is expressed in various neuroectoderm derived tumors and sarcomas. Omburtamab targets B7-H3, an immune checkpoint molecule that is expressed in tumor cells of several cancer types.

Sector

Biotechnology & Medical Research

Calendar

07/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Y-mAbs Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

11.4 USD

Average target price

21.29 USD

Spread / Average Target

+86.72%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
Y-MABS THERAPEUTICS, INC.	+67.16%	500M
VERTEX PHARMACEUTICALS INCORPORATED	+16.61%	122B
REGENERON PHARMACEUTICALS, INC.	+17.75%	112B
ARGENX SE	+17.23%	25.91B
BIONTECH SE	-24.11%	19.33B
GENMAB A/S	-18.56%	16.17B
BEIGENE, LTD.	-18.47%	15.6B
WUXI APPTEC CO., LTD.	-47.75%	14.65B
SAREPTA THERAPEUTICS, INC.	+57.35%	14.34B
NEUROCRINE BIOSCIENCES, INC.	+5.62%	14B

Bio Therapeutic Drugs